MENU

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story